BioMarin Announces Second Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
BioMarin Pharma (BMRN) Q2 Revenues Miss; Reaffirms FY Revs
August 1, 2019 4:59 PM EDTBioMarin Pharma (NASDAQ: BMRN) reported Q2 GAAP EPS of ($0.21), which may not compare to the analyst estimate of ($0.10). Revenue for the quarter came in at $387.8 million versus the consensus estimate of $415.04 million.
GUIDANCE:
BioMarin Pharma reafffirms FY2019 revenue of... More
